Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Vericel (VCEL) Stock Price

News stories about Vericel (NASDAQ:VCEL) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vericel earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.0695425226419 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several analysts have issued reports on the stock. ValuEngine downgraded shares of Vericel from a “hold” rating to a “sell” rating in a report on Friday, December 1st. BTIG Research set a $6.00 price target on shares of Vericel and gave the company a “buy” rating in a report on Monday, October 2nd.

Shares of Vericel (NASDAQ VCEL) opened at $5.00 on Wednesday. Vericel has a fifty-two week low of $2.25 and a fifty-two week high of $6.30. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.22 and a current ratio of 2.50.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. Vericel had a negative net margin of 45.11% and a negative return on equity of 265.45%. The company had revenue of $14.26 million for the quarter. sell-side analysts forecast that Vericel will post -0.6 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Vericel (VCEL) Stock Price” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2017/12/20/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-vericel-vcel-stock-price.html.

Vericel Company Profile

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

Insider Buying and Selling by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply